Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer

Shots:

  • The P-III trial involves assessing Libtayo (300mg, IV, q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The trial enrolled patients regardless of their PD-L1 status
  • The results demonstrated a 31% reduction in the risk of death in the total population, improvement in OS, median survival (12.0 mos. vs 8.5mos). The trial will stop early, following the IDMC recommendation
  • Libtayo is a fully-human mAb targeting the immune checkpoint receptor PD-1 on T-cells. Both the companies plan the regulatory submission of the therapy in 2021

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Livable Limerick

The post Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer first appeared on PharmaShots.